IVIG Privigen denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for ivig privigen are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Privigen for Medical Necessity — and Why You Can Appeal

Privigen (immune globulin intravenous, 10%) is a high-cost IVIG therapy indicated for conditions including primary immunodeficiency (PI), chronic inflammatory demyelinating polyneuropathy (CIDP), and chronic immune thrombocytopenic purpura (ITP). A medical-necessity denial from UnitedHealthcare means UHC's reviewer concluded that your clinical documentation did not sufficiently demonstrate that Privigen meets the plan's criteria for coverage — typically because records were incomplete, did not document disease severity, or did not confirm that required prior steps were satisfied. Medical-necessity denials are among the most commonly overturned denial categories when a strong, well-documented appeal is submitted.

## Why This Denial Is Appealable

UHC's determination is based on the information submitted at the time of the prior authorization request. If your records were incomplete, if the reviewer applied criteria incorrectly, or if your prescriber's clinical judgment was not fully documented, an appeal with a comprehensive evidence package can change the outcome. External review data consistently shows that patients win a significant proportion of medical-necessity appeals, particularly for established therapies with strong clinical guideline support.

## Federal Appeal Framework

• ERISA §503 (employer plans): Guarantees a full-and-fair review, including access to all criteria UHC used and the right to submit additional evidence.
• ACA §2719 / State external review: Available after internal levels are exhausted. An independent external reviewer — not employed by UHC — will evaluate whether the denial was consistent with clinical evidence. Act within approximately four months of your denial notice.
• Expedited review: If your condition is urgent or a gap in therapy poses imminent clinical risk, request expedited processing at every level.

## Your Appeal Process

1. Request the denial letter, UHC's Privigen clinical policy, and the specific criteria cited for denial. 2. Identify the exact gap — missing diagnosis documentation, insufficient severity evidence, or prior-treatment history — and build your package to fill it. 3. File a Level 1 internal appeal within your plan's deadline (printed on the denial notice). 4. If denied internally, escalate to external review without delay.

## Documentation to Gather

• Diagnosis confirmation: Specialist notes, diagnostic workup, laboratory results, and imaging confirming your condition and its severity.
• Clinical severity documentation: Objective measures from your chart — functional assessments, symptom scores, nerve-conduction studies for CIDP, immunoglobulin levels for PI — that establish the degree of impairment. Reference ranges should come from the FDA label and your insurer's own policy, not invented numbers.
• Prior-treatment history: Dates, regimens, durations, and outcomes of all prior therapies tried, with documentation of failure or intolerance.
• Prescriber medical-necessity letter: A detailed, individualized letter from your specialist explaining your diagnosis, disease course, prior treatments, and why Privigen is medically necessary now — citing the applicable guideline organization (e.g., relevant immunology or neurology society guidance) generically.
• Responding physician's credentials: Appeals reviewed by a board-certified specialist in the relevant field carry more weight.

## Criteria-Mapping Strategy

Obtain UHC's published clinical policy for Privigen/IVIG. List every medical-necessity criterion in that policy and in the FDA-approved prescribing information. Then construct a table matching each criterion to specific chart documentation. Leave no criterion unaddressed — gaps in the mapping are the most common reason initial appeals fail.